Breaking News Instant updates and real-time market news.

AGN

Allergan

$168.96

2.84 (1.71%)

, ENDP

Endo

$7.01

0.17 (2.49%)

19:02
03/18/18
03/18
19:02
03/18/18
19:02

President Trump to unveil plan to combat opioid addiction crisis, Reuters says

President Donald Trump is expected to unveil a plan on Monday to combat the opioid addiction crisis that includes seeking the death penalty for drug dealers, according to Reuters, citing White House officials. The plan will also seek to cut opioid prescriptions by a third over the next three years, the report added. Publicly traded companies in the space include Allergan (AGN), Endo International (ENDP), Johnson & Johnson (JNJ), Teva Pharmaceutical (TEVA), AmerisourceBergen (ABC), Cardinal Health (CAH) and McKesson (MCK).Reference Link

AGN

Allergan

$168.96

2.84 (1.71%)

ENDP

Endo

$7.01

0.17 (2.49%)

JNJ

Johnson & Johnson

$133.68

0.62 (0.47%)

TEVA

Teva

$18.37

0.32 (1.77%)

ABC

AmerisourceBergen

$96.61

-0.75 (-0.77%)

CAH

Cardinal Health

$70.95

0.25 (0.35%)

MCK

McKesson

$152.33

-1.63 (-1.06%)

  • 18

    Mar

  • 19

    Mar

  • 21

    Mar

  • 25

    Mar

  • 05

    Apr

  • 24

    Apr

  • 12

    Jun

AGN Allergan
$168.96

2.84 (1.71%)

03/14/18
RBCM
03/14/18
NO CHANGE
RBCM
Outperform
RBC says Allergan sent clear message that all strategic options being evaluated
RBC Capital analyst Randall Stanicky said that Allergan Chairman and CEO Brent Saunders and new CFO Matt Walsh sent a "clear" message while presenting earlier at an investor conference that all strategic options are being evaluated "with a sense of urgency." This message, which he said is the one he had hoped to hear, will keep the asset sale/break-up debate in the stock, said Stanicky. The analyst, who expects the Street's focus on asset sales to pick up following this, keeps an Outperform rating on Allergan shares.
03/05/18
RHCO
03/05/18
INITIATION
Target $24
RHCO
Buy
Evolus initiated with a Buy at SunTrust
SunTrust analyst John Boris initiated Evolus (EOLS) with a Buy rating and a price target of $24. Boris notes that the company is about its launch it first product DWP-450, targeting the $2B global aesthetic toxin market, adding that the treatment has been de-risked with comparable efficacy to Allergan's (AGN) Botox. The analyst anticipates regulatory approval from the FDA and a soft U.S. launch in Q4 of this year.
03/05/18
CANT
03/05/18
INITIATION
Target $25
CANT
Overweight
Evolus initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen started Evolus (EOLS) with an Overweight rating and $25 price target. Physicians want a less costly alternative to Allergan's (AGN) Botox, Chen tells investors in a research note. She expects approval of DWP-450 before the end of the year and notes Evolus is planning to sell the neurotoxin at a 20%-25% discount to Botox.
03/15/18
JPMS
03/15/18
NO CHANGE
Target $265
JPMS
Overweight
Allergan CEO comments on evaluating options a 'clear positive,' says JPMorgan
JPMorgan analyst Chris Schott views Allergan CEO Brent Saunders' comments yesterday on evaluating all options to create value as a "clear positive." The company is focusing on core business execution with a set of near-term pipeline opportunities while also examining other potential value-unlocking options for the business, Schott tells investors in a research note. The analyst says he has long argued that Allergan's core business is "significantly undervalued" and that any shift toward greater Botox/aesthetics exposure would result in a company that trades at a "distinctly higher multiple" than the current business. As such, he believes selling or spinning off assets could unlock value. Schott keeps an Overweight rating on Allergan with a $265 price target.
ENDP Endo
$7.01

0.17 (2.49%)

02/28/18
GABE
02/28/18
DOWNGRADE
GABE
Hold
Endo downgraded to Hold from Buy at Gabelli
02/28/18
GABE
02/28/18
DOWNGRADE
GABE
Hold
Endo downgraded to Hold at Gabelli on soft FY18 outlook
As reported earlier, Gabelli analyst Kevin Kedra downgraded Endo International to Hold from Buy after the company's below-consensus FY18 outlook. Kedra also points to some $8.4B in debt looming over the company as its ability to reduce the burden is restricted by its multiple cash warnings as well as the absence of near-term catalysts.
02/26/18
LEER
02/26/18
NO CHANGE
LEER
Outperform
Potential settlement on Testosterone step in right direction for Endo, says Leerink
Leerink analyst Ami Fadia notes that in the Multidistrict Litigation 2545 regarding Testosterone Replacement Therapy Products Liability Litigation, the parties involved including Endo entered into a Memorandum of Understanding on a potential global settlement. While the analyst acknowledges that investors remain cautious on the ultimate financial impact of the mesh liabilities, she believes this is another step in the right direction that Endo is taking to put the overhang from litigation proceedings behind it. Fadia thinks that as management moves to settle pending litigation, this will shift focus back to the operational aspects of the company, which are "underappreciated."
02/26/18
JMPS
02/26/18
DOWNGRADE
JMPS
Market Perform
Endo downgraded to Market Perform from Outperform at JMP Securities
JMP Securities analyst Donald Ellis downgraded Endo to Market Perform from Outperform, stating that the company has a consistently declining branded base business and base generics business and he believes it has been very difficult for Endo to deleverage its balance sheet. Ellis downgraded the stock to Market Perform as his final rating, as JMP is terminating coverage of Endo International to reallocate research resources.
JNJ Johnson & Johnson
$133.68

0.62 (0.47%)

02/06/18
WELS
02/06/18
NO CHANGE
Target $160
WELS
Outperform
Johnson & Johnson talc litigation concerns appear overblown, says Wells Fargo
Wells Fargo analyst Lawrence Biegelsen says Johnson & Johnson shares were down partly due to concerns about ongoing litigation over allegations that its talcum power products are unsafe for use because they contain asbestos which can cause mesothelioma. Based on prior high-profile product liability cases in the drug and device sectors, the analyst believes any potential settlement would be manageable for Johnson & Johnson. He reiterates an Outperform rating and $160 price target on the shares.
01/18/18
MSCO
01/18/18
NO CHANGE
Target $157
MSCO
Equal Weight
Zytiga ruling a headwind, but doesn't change J&J thesis, says Morgan Stanley
Morgan Stanley analyst David Lewis noted that Johnson & Johnson suffered an adverse Zytiga IPR ruling, which he calls an incremental headwind. However, he added that a possible earlier generic Zytiga entry is irrelevant to his net present value for J&J shares and doesn't change his view that its Pharma growth accelerates in 2018. Lewis keeps an Equal Weight rating and $157 price target on J&J shares.
01/04/18
RBCM
01/04/18
NO CHANGE
Target $54
RBCM
Outperform
Pacira price target raised to $54 from $50 at RBC Capital
RBC Capital analyst Randall Stanicky raised his price target on Pacira (PCRX) to $54 and kept his Outperform rating. Stanicky says his focus is on the company's expected pre-announcement for Q4 this week and his upcoming discussion with CEO Dave Stack on Monday regarding changes from CMS around unbundling of payments that could represent a game changing opportunity for the company's EXPAREL. The analyst notes that traction is building around Pacira's relationship with Johnson & Johnson (JNJ) on the ortho selling side, which marks about half of its revenue.
01/02/18
01/02/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) downgraded to Neutral from Overweight at JPMorgan with analyst Michael Weinstein saying he sees greater upside potential in other large cap names with J&J shares trading at 17.9 times his 2018 earnings estimate. 2. PG&E (PCG) downgraded to Sell from Neutral at Guggenheim and to Neutral from Buy at Goldman Sachs. Goldman analyst Michael Lapides saying resolution of claims from the California wildfires, if inverse condemnation is applied, could take years and "cash flow/balance sheet impacts could prove significant still." 3. Allstate (ALL) downgraded to Underperform from Market Perform at Keefe Bruyette with analyst Meyer Shields saying the company's margin expansion story has played out. 4. Cabot Oil & Gas (COG) downgraded two notches to Underperform from Outperform at Raymond James with analyst John Freeman citing valuation after "considerable" 2017 share outperformance. 5. Windstream (WIN) downgraded to Underweight from Neutral at JPMorgan with analyst Philip Cusick saying he sees fundamental business challenges continuing in both the near and long term. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
TEVA Teva
$18.37

0.32 (1.77%)

02/12/18
02/12/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Nasdaq (NDAQ) upgraded to Outperform from Market Perform at Wells Fargo by analyst Christopher Harris, who said the company is at an inflection point where both its trading and non-trading segments will begin to generate faster growth. He sees a "pathway to much higher profit margin" over the next two years and believes the stock is "relatively inexpensive" at a discount to the S&P 500 Index. 2. Teva (TEVA) upgraded to Outperform from Neutral at Credit Suisse by analyst Vamil Divan. The analyst sees "early execution" towards the company's restructuring plan and believes its 2018 outlook is achievable. He feels expectations are now reasonable believes the upside path is now clearer. 3. Cisco Systems (CSCO) upgraded to Buy from Neutral at Nomura Instinet by analyst Jeffrey Kvaal to reflect the webscale uptick and believes tax reform and the company's recurring revenue transition provide downside protection. Kvaal believes the recent pullback in Cisco shares provides a buying opportunity. 4. Tallgrass Energy Partners (TEP) upgraded to Overweight from Equal Weight at Barclays by analyst Christine Cho, who lowered her price target to $43 from $50. The analyst said her analysis suggests a Tallgrass Energy GP (TEGP) acquisition of Tallgrass Energy Partners is the most likely scenario. She valued Tallgrass Energy Partner at $43 in this scenario. 5. VF Corp (VFC) upgraded to Buy from hold at Stifel by analyst Jim Duffy, who sees fiscal 2019 consensus estimates rising throughout the year due to fundamental strength, environmental factors, and currency. Duffy believes VF shares can sustain the premium multiple for the "foreseeable future." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/21/18
DBAB
02/21/18
NO CHANGE
Target $20
DBAB
Hold
Deutsche sees rifamycin as possible long-term threat to Valeant
The outlook for Valeant Pharmaceuticals' (VRX) Xifaxan, which represents 13% of the company's revenue, improved last year following safety issues for competitor Viberzi and delays for generic challenger Teva (TEVA), Deutsche Bank analyst Gregg Gilbert tells investors in a research note. More recently, the analyst notes, questions have been raised as to whether Cosmo's rifamycin could pose a threat to Xifaxan, either in the near term from off-label prescribing for irritable bowel syndrome with diarrhea, or longer term if eventually approved for IBS-D. After due diligence, Gilbert believes rifamycin could potentially be a longer-term threat to Xifaxan if it works for IBS-D, but he does not see "material risk" from off-label use in the interim. His model continues to assume mid-single digit Xifaxan sales growth for several years and a generic cliff in 2025. The analyst keeps a Hold rating on Valeant with a $20 price target.
02/13/18
WELS
02/13/18
NO CHANGE
WELS
Teva generic comes earlier than expected, says Wells Fargo
Wells Fargo analyst David Maris says Momenta Pharmaceuticals' (MNTA) generic approval of Teva Pharmaceutical's (TEVA) Copaxone came earlier than expected. As recently as the Q4 conference call on February 8, Teva management expected that another generic Copaxone approval would not come until April 2018, Maris tells investors in a research note. The analyst's forecasts assume a continued erosion of Copaxone sales, with sales of $700M in Q1, $500M sales in Q2 and $400M in Q3 and Q4. Maris keeps an Underperform rating on Teva.
02/12/18
FBCO
02/12/18
UPGRADE
Target $23
FBCO
Outperform
Credit Suisse upgrades Teva to Outperform amid execution on restructuring
Credit Suisse analyst Vamil Divan upgraded Teva Pharmaceutical to Outperform from Neutral and raised his price target for the shares to $23 from $20. The analyst sees "early execution" towards the company's restructuring plan and believes its 2018 outlook is achievable. He feels expectations are now reasonable believes the upside path is now clearer.
ABC AmerisourceBergen
$96.61

-0.75 (-0.77%)

03/05/18
ARGS
03/05/18
NO CHANGE
Target $115
ARGS
Buy
AmerisourceBergen price target raised to $115 from $100 at Argus
Argus analysts David Toung and Marisa Janeczek raised their price target on AmerisourceBergen (ABC) to $115, saying the company's Q1 earnings were marked by "solid results in pharma distribution, specialty distribution, and consulting and logistics services". The analysts keeps their Buy rating on the stock, adding that despite the termination of merger talks with Walgreen Boots (WBA), there are strong growth opportunities for the stock as the company begins operations at six new distribution centers. Toung and Janeczek note that the 7% pullback in the stock price marks a favorable entry point.
03/08/18
LEHM
03/08/18
INITIATION
Target $104
LEHM
Equal Weight
AmerisourceBergen initiated with an Equal Weight at Barclays
Barclays analyst Steve Valiquette started AmerisourceBergen with an Equal Weight rating and $104 price target. The analyst initiated 14 companies in Health Care Services with a Neutral industry view.
02/27/18
COWN
02/27/18
NO CHANGE
Target $108
COWN
Outperform
AmerisourceBergen selloff on CNBC report brings buying opportunity, says Cowen
The selloff in shares of AmerisourceBergen (ABC) after CNBC reported that discussions with Walgreens Boots Alliance (WBA) regarding a merger have ended with no agreement presents a buying opportunity, Cowen analyst Charles Rhyee tells investors in an intraday research note. AmerisourceBergen is down 5%, or $4.98, to $95.60 in afternoon trading. The company's underlying fundamentals "remain on solid footing" and current valuation levels "still look compelling," Rhyee contends. The analyst keeps an Outperform rating on AmerisourceBergen with a $108 price target.
02/27/18
BOFA
02/27/18
INITIATION
Target $111
BOFA
Buy
AmerisourceBergen reinstated with a Buy at BofA/Merrill
BofA/Merrill analyst Michael Cherny reinstated coverage on AmerisourceBergen with a Buy and $111 price target.
CAH Cardinal Health
$70.95

0.25 (0.35%)

02/27/18
BOFA
02/27/18
INITIATION
Target $69
BOFA
Underperform
Cardinal Health reinstated with an Underperform at BofA/Merrill
BofA/Merrill analyst Michael Cherny reinstated coverage on Cardinal Health with an Underperform and $69 price target.
02/14/18
JEFF
02/14/18
NO CHANGE
JEFF
Amazon focusing on bolstering medical device distribution, says Jefferies
Yesterday's Wall Street Journal report and a recent scan of job postings still point to Amazon.com's (AMZN) focus on bolstering its medical device/supplies distribution capabilities, specifically targeting hospitals, Jefferies analyst Brian Tanquilut. These postings support a negative thesis for Cardinal Health (CAH), Owens & Minor (OMI) and Premier's (PINC) medical supplies businesses, the analyst adds. Further, he sees the news as an incremental positive for AmerisourceBergen (ABC), McKesson (MCK), CVS Health (CVS) and Walgreens Boots Alliance (WBA) since it further supports the view that Amazon isn't looking to enter the prescription business near-term.
01/04/18
EVER
01/04/18
INITIATION
Target $67
EVER
In Line
Cardinal Health initiated with an In Line at Evercore ISI
Evercore ISI started Cardinal Health with an In Line rating and $67 price target.
03/08/18
LEHM
03/08/18
INITIATION
Target $74
LEHM
Equal Weight
Cardinal Health initiated with an Equal Weight at Barclays
Barclays analyst Steve Valiquette started Cardinal Health with an Equal Weight rating and $74 price target. The analyst initiated 14 companies in Health Care Services with a Neutral industry view.
MCK McKesson
$152.33

-1.63 (-1.06%)

02/27/18
BOFA
02/27/18
INITIATION
Target $179
BOFA
McKesson reinstated with a Buy at BofA/Merrill
BofA/Merrill analyst Michael Cherny reinstated coverage on McKesson with a Buy and $179 price target.
03/08/18
LEHM
03/08/18
INITIATION
Target $165
LEHM
Equal Weight
McKesson initiated with an Equal Weight at Barclays
Barclays analyst Steve Valiquette started McKesson with an Equal Weight rating and $165 price target. The analyst initiated 14 companies in Health Care Services with a Neutral industry view.
02/27/18
BOFA
02/27/18
INITIATION
Target $179
BOFA
Buy
McKesson reinstated with a Buy at BofA/Merrill
BofA/Merrill analyst Michael Cherny reinstated coverage on McKesson with a Buy and $179 price target.

TODAY'S FREE FLY STORIES

COUP

Coupa Software

$46.67

-0.61 (-1.29%)

21:29
04/22/18
04/22
21:29
04/22/18
21:29
Initiation
Coupa Software initiated  »

Goldman starts Coupa…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HBI

Hanesbrands

$17.22

-0.385 (-2.19%)

21:10
04/22/18
04/22
21:10
04/22/18
21:10
Upgrade
Hanesbrands rating change  »

Hanesbrands upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

CYOU

Changyou.com

$30.33

-0.16 (-0.52%)

21:07
04/22/18
04/22
21:07
04/22/18
21:07
Downgrade
Changyou.com rating change  »

Changyou.com downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

KSU

Kansas City Southern

$112.00

1.76 (1.60%)

21:07
04/22/18
04/22
21:07
04/22/18
21:07
Upgrade
Kansas City Southern rating change  »

Kansas City Southern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 03

    May

COUP

Coupa Software

$46.67

-0.61 (-1.29%)

21:07
04/22/18
04/22
21:07
04/22/18
21:07
Initiation
Coupa Software initiated  »

Coupa Software initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STT

State Street

$99.64

-4.57 (-4.39%)

21:07
04/22/18
04/22
21:07
04/22/18
21:07
Upgrade
State Street rating change  »

State Street upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 26

    Apr

HAL

Halliburton

$51.95

-0.06 (-0.12%)

, HAS

Hasbro

$82.89

-1.1 (-1.31%)

20:25
04/22/18
04/22
20:25
04/22/18
20:25
Earnings
Notable companies reporting before Monday's open »

Notable companies…

HAL

Halliburton

$51.95

-0.06 (-0.12%)

HAS

Hasbro

$82.89

-1.1 (-1.31%)

ALK

Alaska Air

$65.39

-0.165 (-0.25%)

KMB

Kimberly-Clark

$100.04

-3.3 (-3.19%)

LII

Lennox

$196.93

-5.755 (-2.84%)

LECO

Lincoln Electric

$92.68

-0.21 (-0.23%)

TCF

TCF Financial

$22.67

-0.11 (-0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 25

    Apr

  • 27

    Apr

  • 01

    May

  • 22

    May

  • 29

    May

  • 30

    May

  • 12

    Jun

VIA

Viacom

$35.35

-0.25 (-0.70%)

, VIAB

Viacom

$30.65

-0.1 (-0.33%)

19:29
04/22/18
04/22
19:29
04/22/18
19:29
Hot Stocks
On The Fly: Top five weekend stock stories »

Catch up on the…

VIA

Viacom

$35.35

-0.25 (-0.70%)

VIAB

Viacom

$30.65

-0.1 (-0.33%)

EPD

Enterprise Products

$26.60

-0.03 (-0.11%)

MMP

Magellan Midstream

$65.16

-0.755 (-1.15%)

MPLX

MPLX

PAA

Plains All American

$24.68

0.42 (1.73%)

GOOG

Alphabet

$1,072.73

-15.18 (-1.40%)

GOOGL

Alphabet Class A

$1,076.64

-12.83 (-1.18%)

AMZN

Amazon.com

$1,527.39

-29.57 (-1.90%)

FB

Facebook

$166.29

-1.82 (-1.08%)

AAPL

Apple

$165.71

-7.08 (-4.10%)

MSFT

Microsoft

$95.01

-1.1 (-1.14%)

BIDU

Baidu

$232.38

-4.73 (-1.99%)

BABA

Alibaba

$179.07

-2.14 (-1.18%)

INTC

Intel

$51.53

-0.68 (-1.30%)

NVDA

Nvidia

$228.74

-0.21 (-0.09%)

CCL

Carnival

$65.88

0.82 (1.26%)

RCL

Royal Caribbean

$119.11

1.18 (1.00%)

NCLH

Norwegian Cruise Line

$55.65

0.71 (1.29%)

DIS

Disney

$100.24

-0.64 (-0.63%)

GIS

General Mills

$43.41

-0.61 (-1.39%)

DAL

Delta Air Lines

$55.40

0.34 (0.62%)

GM

General Motors

$37.61

-0.16 (-0.42%)

TPR

Tapestry

$53.03

-0.255 (-0.48%)

FSNUY

Fresenius SE

AKRX

Akorn

$19.68

0.31 (1.60%)

TCEHY

Tencent

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 23

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 01

    May

  • 01

    May

  • 03

    May

  • 04

    May

  • 04

    May

  • 08

    May

  • 08

    May

  • 10

    May

  • 22

    May

  • 23

    May

  • 30

    May

  • 20

    Jun

  • 26

    Jun

  • 29

    Jun

TCEHY

Tencent

18:45
04/22/18
04/22
18:45
04/22/18
18:45
Periodicals
Tencent Music Entertainment prepares IPO, WSJ reports »

Tencent Music…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TAHO

Tahoe Resources

$5.39

-0.05 (-0.92%)

18:13
04/22/18
04/22
18:13
04/22/18
18:13
Hot Stocks
Tahoe Resources labor strike at La Arena mine in Peru »

Tahoe Resources reports a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

LUV

Southwest

$54.76

-0.02 (-0.04%)

17:56
04/22/18
04/22
17:56
04/22/18
17:56
Periodicals
Southwest cancels 40 flights for inspection, Reuters reports »

Southwest Airlines said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 10

    May

TWX

Time Warner

$96.23

-0.34 (-0.35%)

, CMCSA

Comcast

$33.21

-0.28 (-0.84%)

17:04
04/22/18
04/22
17:04
04/22/18
17:04
Hot Stocks
Box Office Battle: 'A Quiet Place' reclaims first place with $22M »

Paramount's (VIAB)…

TWX

Time Warner

$96.23

-0.34 (-0.35%)

CMCSA

Comcast

$33.21

-0.28 (-0.84%)

CMCSK

Comcast

SNE

Sony

$49.76

0.03 (0.06%)

FOX

21st Century Fox

$36.21

-0.46 (-1.25%)

FOXA

21st Century Fox

$36.69

-0.51 (-1.37%)

LGF.A

Lionsgate

$25.76

-0.44 (-1.68%)

DIS

Disney

$100.24

-0.64 (-0.63%)

VIAB

Viacom

$30.65

-0.1 (-0.33%)

VIA

Viacom

$35.35

-0.25 (-0.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 08

    May

  • 09

    May

  • 09

    May

BAC

Bank of America

$30.26

0.06 (0.20%)

, WFC

Wells Fargo

$52.57

1.02 (1.98%)

16:40
04/22/18
04/22
16:40
04/22/18
16:40
Periodicals
Big banks push mortgage apps, websites as home lending slows, Reuters reports »

Big U.S. banks are racing…

BAC

Bank of America

$30.26

0.06 (0.20%)

WFC

Wells Fargo

$52.57

1.02 (1.98%)

JPM

JPMorgan

$111.47

-0.26 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 25

    Apr

  • 15

    May

  • 16

    May

  • 30

    May

  • 13

    Jul

  • 12

    Oct

AMZN

Amazon.com

$1,527.39

-29.57 (-1.90%)

16:34
04/22/18
04/22
16:34
04/22/18
16:34
Periodicals
Amazon to broaden offering in groceries in India, Reuters says »

Amazon expects groceries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

F

Ford

$10.82

-0.14 (-1.28%)

, WPP

WPP

$80.16

-1.21 (-1.49%)

16:27
04/22/18
04/22
16:27
04/22/18
16:27
Periodicals
Ford to take bids on some advertising managed by WPP, Reuters reports »

Ford (F) said it will…

F

Ford

$10.82

-0.14 (-1.28%)

WPP

WPP

$80.16

-1.21 (-1.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

FB

Facebook

$166.29

-1.82 (-1.08%)

16:23
04/22/18
04/22
16:23
04/22/18
16:23
Periodicals
Facebook sets lobbying record, Axios reports »

Facebook spent $3.3M on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

AKRX

Akorn

$19.68

0.31 (1.60%)

, FSNUY

Fresenius SE

16:19
04/22/18
04/22
16:19
04/22/18
16:19
Hot Stocks
Akorn responds to Fresenius decision to terminate merger agreement »

Akorn (AKRX) issued a…

AKRX

Akorn

$19.68

0.31 (1.60%)

FSNUY

Fresenius SE

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INFY

Infosys

$17.38

0.21 (1.22%)

15:34
04/22/18
04/22
15:34
04/22/18
15:34
Conference/Events
Infosys to host analyst meeting »

Analyst meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKRX

Akorn

$19.68

0.31 (1.60%)

, FSNUY

Fresenius SE

14:08
04/22/18
04/22
14:08
04/22/18
14:08
Hot Stocks
Fresenius terminates merger agreement with Akorn over data breaches »

Fresenius (FSNUY) decided…

AKRX

Akorn

$19.68

0.31 (1.60%)

FSNUY

Fresenius SE

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LEVB

Level Brands

$5.15

0.25 (5.10%)

12:20
04/22/18
04/22
12:20
04/22/18
12:20
Conference/Events
Level Brands CEO Sumichrast interview to air on The RedChip Money Report »

Marty Sumichrast,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

LEVB

Level Brands

$5.15

0.25 (5.10%)

04:55
04/22/18
04/22
04:55
04/22/18
04:55
Conference/Events
Level Brands CEO Sumichrast interview to air on The RedChip Money Report »

Marty Sumichrast,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

04:55
04/22/18
04/22
04:55
04/22/18
04:55
Conference/Events
International Monetary Fund & World Bank Group to co-host an annual meeting »

2018 Spring Meeting will…

CGNT

Cogentix Medical

$3.84

-0.005 (-0.13%)

19:21
04/21/18
04/21
19:21
04/21/18
19:21
Hot Stocks
Laborie Medical announces completion of tender offer for Cogentix Medical »

Laborie Medical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSG

The Stars Group

$29.35

0.4 (1.38%)

, SKYAY

Sky

18:31
04/21/18
04/21
18:31
04/21/18
18:31
Hot Stocks
The Stars Group to acquire Sky Betting & Gaming for $4.7B »

The Stars Group (TSG)…

TSG

The Stars Group

$29.35

0.4 (1.38%)

SKYAY

Sky

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LUV

Southwest

$54.76

-0.02 (-0.04%)

18:22
04/21/18
04/21
18:22
04/21/18
18:22
Hot Stocks
Southwest responds to Emergency Airworthiness Directive »

Southwest Airlines said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 10

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.